ASCO 2019 and the future of oncology/ Oncology/ Views & Analysis/ Views and analysis ASCO 2019 round-up Mike Smith ASCO 2019, kantar, Oncology 0 Comment With the American Society of Clinical Oncology (ASCO) conference over for another year, Richard Staines presents a round-up Share X ASCO 2019 round-up https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-round-up/
ASCO 2019 and the future of oncology/ Oncology/ Video/ Views & Analysis/ Views and analysis ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trial mike.smith@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment Kantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last Share X ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trial https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/kantar-macrogenics-phase-3-sophia-trial/
ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis ASCO 2019 – phase I data generates hope for the future mike.hammerton@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment Sometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future. Share X ASCO 2019 – phase I data generates hope for the future https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/amgen-kras-amg510-phase-i-data/
ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis ASCO 2019 – Enfortumab comes out fighting in bladder cancer mike.hammerton@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment At ASCO 2019, results were presented from the phase II EV-201 trial, which evaluated antibody drug conjugate (ADC) Share X ASCO 2019 – Enfortumab comes out fighting in bladder cancer https://pharmaphorum.com/video/asco-2019-enfortumab-bladder-cancer/
ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis ASCO 2019 – Kantar highlights a selection of exciting Phase I and Phase II results mike.hammerton@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment At ASCO, a lot of attention is given to the results of the large, clinical practices changing phase Share X ASCO 2019 – Kantar highlights a selection of exciting Phase I and Phase II results https://pharmaphorum.com/video/asco-2019-results-clinical-practices-changing-phase-iii-studies/
ASCO 2019 and the future of oncology/ News/ News/ Oncology Relax criteria to increase sign-ups to cancer trials, says ASCO Richard Staines cancer, lung cancer, R&D 0 Comment Only 3% of patients with cancer in the US enrol on a clinical trial – and the American Share X Relax criteria to increase sign-ups to cancer trials, says ASCO https://pharmaphorum.com/news/relax-criteria-to-increase-sign-ups-to-cancer-trials-says-asco/
ASCO 2019 and the future of oncology/ News/ News/ Oncology Gilead highlights Yescarta survival data in ASCO update Phil Taylor blood cancer, cancer, CAR T, Gilead, Kite 0 Comment Gilead’s Kite subsidiary has reported new data from the main trial for its CAR-T Yescarta, hoping to encourage Share X Gilead highlights Yescarta survival data in ASCO update https://pharmaphorum.com/news/gilead-highlights-yescarta-survival-data-in-asco-update/
ASCO 2019 and the future of oncology/ News/ News/ Oncology/ Top stories Sanofi trumpets Darzalex rival isatuximab in refractory myeloma Phil Taylor ASCO 2019, cancer, myeloma, Oncology 0 Comment Sanofi’s plans for a comeback in cancer have taken a step forward with new data on its anti-CD38 Share X Sanofi trumpets Darzalex rival isatuximab in refractory myeloma https://pharmaphorum.com/news/sanofi-darzalex-rival-isatuximab-refractory-myeloma/
ASCO 2019 and the future of oncology/ News/ News/ Oncology Astellas/Seattle Genetics target advanced bladder cancer with enfortumab vedotin Richard Staines Astellas, bladder cancer, cancer, Seattle Genetics 0 Comment Roche and Merck & Co have got their respective immunotherapies Tecentriq and Keytruda approved in bladder cancer – Share X Astellas/Seattle Genetics target advanced bladder cancer with enfortumab vedotin https://pharmaphorum.com/news/astellas-seattle-genetics-target-advanced-bladder-cancer-with-enfortumab-vedotin/
